Dr. Zambon joined KGI in July 2014. Dr. Zambon’s research interests involve understanding how cell signaling pathways and transcriptional circuits drive cardiovascular development and remodeling during development and disease. His PhD training at the University of California San Diego was in applying molecular and pharmacological approaches for elucidating cell-type specific signaling events downstream of G-protein coupled receptors; one of largest classes of therapeutic drug targets.
Dr. Zambon’s postdoctoral training at the Gladstone Institute of Cardiovascular Disease/UCSF was in genomics and systems biology, where he became interested in applying evolutionary conservation and genomic sequence information to predict, in an unbiased way, the transcriptional circuits and downstream pathways that drive cell fate decisions. The focus of his current work is in integrating molecular, pharmacological and systems biology approaches to control cell fate decisions both in vitro and in vivo for cardiac tissue engineering and repair. Long-term goals of his research are to identify new pharmacological, genetic or cell-based therapeutic strategies for treatment of heart disease in adults and children. He has received both independent and collaborative grants from the American Heart Association and the National Institutes of Health.
Gan Z, Wang J, Salomonis N, Stowe JC, Haddad GG, McCulloch AD, Altintas I, Zambon AC. (2014) MAAMD: A workflow to standardize meta-analysis of Affymetrix microarray data. BMC Bioinformatics. 15:69.
Dubchak I, Munoz M, Poliakov A, Salomonis N, Minovitsky S, Bodmer R, Zambon AC. (2013) Whole-Genome rVISTA: A Tool to Determine Enrichment of Transcription Factor Binding Sites in Gene Promoters from Transcriptomic Data. Bioinformatics. 29(16):2059-61.
Ling H, Gray CB, Zambon AC, Grimm M, Gu Y, Dalton N, Purcell NH, Peterson K, Brown JH. (2013) CaMKIIδ mediates myocardial ischemia/reperfusion injury through NF-kB. Circ Res. 112: 935-44.
Yamazaki KG, Gonzalez E, Zambon AC (2012) Angiotensin II, acting via the AT1 receptor, mediates pro-fibrotic effects of advanced glycation end products (AGE) on cultured rat cardiac fibroblasts. J Cardiovasc Transl Res. 5: 805-813.
Zambon AC, Gaj S, Ho I, Hanspers K, Vranizan K, Conklin BR, Pico AR, Evelo CT, Salomonis N (2012) GO-Elite: A flexible solution for pathway and ontology overrepresentation. Bioinformatics. Aug 15; 28(16): 2209-10.
Insel PA, Zhang L, Murray F, Yokouchi H, Zambon AC (2012) Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol. 204: 277-87.
Salomonis N, Schlieve CR, Pereira L, Wahlquist C, Colas A, Zambon AC, Vranizan K, Spindler MJ, Pico AR, Cline MS, Clark TA, Williams A, Blume JE, Samal E, Mercola M, Merrill BJ, Conklin BR (2010) Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci USA. 107:10514-9.
Zambon AC (2010) The Ki67 promoter labels cell cycle entry in living cells. Cytometry. 77:564-70.
Zambon AC, Zhang L, Minovitsky S, Kantor J, Prabhakar S, Salomonis N, Vranizan K, Dubchak I, Conklin BR, Insel PA (2005) Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci USA, 102: 8561-6.
*Selected publications from 31 in PubMed